Agios Pharmaceuticals (NASDAQ:AGIO) has been given a $115.00 price objective by stock analysts at SunTrust Banks in a report issued on Monday, May 7th. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. SunTrust Banks’ target price indicates a potential upside of 33.71% from the stock’s previous close. SunTrust Banks also issued estimates for Agios Pharmaceuticals’ Q2 2018 earnings at ($1.69) EPS, Q3 2018 earnings at ($1.73) EPS, Q4 2018 earnings at ($1.67) EPS, FY2018 earnings at ($6.73) EPS, FY2019 earnings at ($6.30) EPS, FY2020 earnings at ($5.90) EPS, FY2021 earnings at ($3.15) EPS and FY2022 earnings at ($0.90) EPS.
Other equities research analysts have also issued reports about the stock. ValuEngine raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Zacks Investment Research raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 price target on the stock in a report on Tuesday, January 9th. Needham & Company LLC boosted their target price on shares of Agios Pharmaceuticals from $72.00 to $86.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 16th. Finally, Credit Suisse Group set a $95.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, April 11th. Four research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $88.40.
Agios Pharmaceuticals opened at $86.01 on Monday, MarketBeat Ratings reports. Agios Pharmaceuticals has a 12 month low of $85.15 and a 12 month high of $86.25.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Friday, May 4th. The biopharmaceutical company reported ($1.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.60) by ($0.03). The company had revenue of $8.80 million for the quarter, compared to the consensus estimate of $11.93 million. Agios Pharmaceuticals had a negative net margin of 822.32% and a negative return on equity of 61.70%. The company’s revenue for the quarter was down 16.2% compared to the same quarter last year. During the same period last year, the firm posted ($1.56) earnings per share. research analysts expect that Agios Pharmaceuticals will post -6.51 EPS for the current year.
In other news, insider Steven L. Hoerter sold 2,050 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $78.63, for a total value of $161,191.50. Following the transaction, the insider now owns 2,050 shares in the company, valued at approximately $161,191.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Scott Biller sold 3,000 shares of the business’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $83.08, for a total transaction of $249,240.00. The disclosure for this sale can be found here. Insiders sold a total of 62,950 shares of company stock worth $5,102,838 in the last 90 days. Corporate insiders own 3.02% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in AGIO. Lord Abbett & CO. LLC lifted its position in shares of Agios Pharmaceuticals by 175.8% during the 1st quarter. Lord Abbett & CO. LLC now owns 1,044,346 shares of the biopharmaceutical company’s stock valued at $85,407,000 after acquiring an additional 665,684 shares during the period. Baillie Gifford & Co. bought a new stake in Agios Pharmaceuticals during the 1st quarter valued at $47,607,000. BlackRock Inc. increased its stake in Agios Pharmaceuticals by 14.0% during the 1st quarter. BlackRock Inc. now owns 3,206,053 shares of the biopharmaceutical company’s stock valued at $262,192,000 after purchasing an additional 393,336 shares in the last quarter. Point72 Asset Management L.P. increased its stake in Agios Pharmaceuticals by 343.8% during the 1st quarter. Point72 Asset Management L.P. now owns 406,090 shares of the biopharmaceutical company’s stock valued at $33,210,000 after purchasing an additional 314,590 shares in the last quarter. Finally, UBS Asset Management Americas Inc. increased its stake in Agios Pharmaceuticals by 965.5% during the 4th quarter. UBS Asset Management Americas Inc. now owns 345,284 shares of the biopharmaceutical company’s stock valued at $19,740,000 after purchasing an additional 312,878 shares in the last quarter. Institutional investors own 82.13% of the company’s stock.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.